The impact of biomics technology and DNA directed anti-obesity targeting of the brain reward circuitry

Gene Therapy and Molecular Biology

Volumn 12, Issue 1, 2008, Pages 45-68

  Chen, Amanda L C ^a   Blum, Kenneth ^b,d,f,h   Chen, Thomas J H ^a   Reinking, Jeffrey ^c   Waite, Roger L ^d   Downs, Bernard W ^d,e   Braverman, Eric R ^f,g   Arcuri, Vanassa ^f   Kerner, Mallory ^f   Notaro, Alison ^e   Cassel, Kimberly ^h   Blum, Seth H ^h   Bagchi, Debasis ⁱ   Bagchi, Manashi ^i,j   Robarge, Ariel ^e   Kaats, Gilbert ^k   Comings, David E ^l,o   Rhoades, Patrick ^m   Williams, Lonna ^d   Tung, Howard ⁿ  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LifeGen Inc   (United States)

^e Allied Nutraceutical Research   (United States)

^f Path Medical Research Foundation   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h Synaptamine Inc   (United States)

ⁱ CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^j InterHealth Nutraceuticals Inc   (United States)

^k The City of San Antonio Metropolitan Health District   (United States)

^l Carlsbad Science Foundation   (United States)

^m Central Valley Comprehensive Obesity Clinic   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

"Neurobesigenics"; Dopamine; Genotrim; Nutrigenomics; Pleiotropic disease; Polymorphisms; Reward cascade; Reward Deficiency Syndrome (RDS)

Indexed keywords

PASSIFLORA;

EID: 50849115200     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Adler CM, Elman I, Weisenfeld N, Kestler L, Pickar D, Breier A (2000) Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharma 2, 545-550.
2. Afman L, Muller M (2006) Nutrigenomics: From Molecular Nutrition to Prevention of Disease. J Am Diet Assoc 106, 569-576.
3. Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M ( 2001a) Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 26, 369-273.
4. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M (2001b) Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 26, 63-67.
5. Ashrafi K, Chang FY, Watts JL, Fraser Ag, Kamath RS, Ahringer J, Ruvkun G (2003) Genome-wide RNAi analysis of Caenarhaditis clegans fat regulatory genes. Nature 421, 268-272.
6. Bagchi SP, Smith TM (1979) Synaptosomal dopamine from phenylalanine in brain: effects of some dopaminergic agents. Res Comm Chem Pathol Pharmacol 26, 447-458.
7. Balcioglu A, Wurtman RJ (2000) Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat stri atal and hypothalamic extracellular fluid. Neuropharmacology 39, 2352-2359.
8. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, Wess J (2002) Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci 99, 11452-11457.
9. Bello NT, Sweigart KL, Lakoski JM, Norgren R, Hajnal A (2003) Restricted feeding with scheduled sucrose access results in an upregulation of the rat dopamine transporter. Am J Physiol Regul Integr Comp Physiol 284, R1260-1268.
10. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH ( 1996) Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 12, 81-84.
11. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A, Maldonado R (2005) Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci 25, 1103-1112.
12. Biebermarm H, Castaneda TR, van Landeghem F, von Deimling A, Escher F, Brabant G, Hebebrand J, Hinney A, Tschop MH, Gruters A, Krude H (2006) A role for β-melanocyte- stimulating hormone in human body-weight regulation. Cell Metab 3, 141-146.
13. Bina KG, Cincotta AH (2000) Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin- releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 71, 68-78.
14. Blum K, Allison D, Trachtenberg MC, Williams RW, Loeblich LA (1988c) Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient Tropamine. Curr Ther Res 43, 1204-1214.
15. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE (2000) Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 32(Suppl:i-iv), 1-112.
16. Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG (1996b ken) Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics 6, 297-305.
17. Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM (2006c) Genotrim™ a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses 68, 844-52.
18. Blum K, Chen TJH, Downs WB, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy, Deutch R, Pons, MM, Meshkin B (2006a) Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther 23, 1040-51.
19. Blum K, Chen TJH, Downs,WB, Meshkin B, Blum SH, Pons MM, Mengucci JF, Waite RL, Arcuri V, Varshofsiky M, Braverman ER (2006b) Synaptamine (SG8839) ™ an amino-acid enkephatinase inhibitor nutraceutical Improves recovery of alcoholics, a subtype of Reward deficiency syndrome(RDS). Trends in Applied Sciences Research 2, 132-138.
20. Blum K, Chen TJH, Meshkin B, Waite RL, Downs WB, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Paloma T (2007) Manipulation of Catechol -O Methyl Transferase (COMT)Activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms. A Hypothesis Med Hyp 69, 1054-60.
21. Blum K, Cull JG, Chen TJH, Garcia-Swan S, Holder JM, Wood R, Braverman ER, Buci LR, Trachtenberg MC (1997) Clinical evidence For Effectiveness of Phencal TM in maintaining weight loss in an open-label, controlled, 2-year study. Curr Their Res 58, 745-763.
22. Blum K, Meshkin B, Downs BW (2006d) DNA based customized nutraceirtical "gene therapy" utilizing a genoscore: A hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory process in the human. Med Hypoth 66, 1008-1018.
23. Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, Ozkaragoz T, Fitch RJ, Sadlack F, Sheffield, D, Dahlmann T, Halbardier S, Nogami H (1991) Association of the At allele of the D2 doparnine receptor gene with severe alcoholism. Alcohol 8, 409-416.
24. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB (1990) Allelic association of human doparnine D2 receptor gene in alcoholism. JAMA 263, 2055-2060.
25. Blum K, Noble, EP, Volkow ND, Url G, Comings DE (2001) 1st Conference on Reward Deficiency Syndrome: Genetic Antecedents and Clinical Pathways. San Francisco, California, USA. Mol Psychiatry 6 Supp; S1-8.
26. Blum K, Payne J (1991) Alcohol and The Addictive Brain" The Free Press (Simon and Schuster), New York, NY.
27. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE) ( 1995) Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5, 121-41.
28. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE (1996a) The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89, 396-400.
29. Blum K, Trachtenberg MC, Cook DW (1990) Neuronutrient effects on weight loss in carbohydmte bingers: An open clinical trial. Curr Their Res 48, 217-233.
30. Blum K, Trachtenberg MC, Elliott CE, Dingler ML, Sexton RL, Samuels At, Cataldie L (1988b) Enkephalinase inhibition and precursor amino acid loading improves Inpatient treatment of alcohol and polydrug abusers: Double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol 5481493
31. Blum K, Trachtenberg MC, Ramsey J (1988a) Improvement of In Patient treatment of the alcoholic as a function of neuronutrient restoration: A pilot study. Int J Addiction 23, 991-998.
32. Blum K, Wallace JE, Trachtenberg MC (1987) Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. Alcohol 4,449-456.
33. Blum K. Sheridan PJ, Wood RC, Braverman ER, Chen TJH, Cull JG, Comings DE (1996b) The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89, 396-400.
34. Boettiger CA, Mitchell JM, Tavares VC, Robertson M, Joslyn G, D'Esposito M, Fields HL (2007) Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype. J Neurosci 27, 14383-14391.
35. Bongiovanni R, Young D, Newbould E, Jaskiw GE (2006) Increased striatal dopamine synthesis is associated with decreased tissue levels of tyrosine. Brain Res 1115, 26-36.
36. Bowirrat A, Oscar-Berman M (2005) Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet 132, 29-37.
37. Brandacher G, Winkler C, Aigner F, Schwelberger H, Schroecksnadel K, Margreiter R, Fuchs D, Weiss HG (2006) Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes Surg 16,,541-548.
38. Brown RJ, Blum K, Trachtenberg MC (1990) Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. J Psychoact Drugs 22, 173-187.
39. Brown RP, Gerbarg PL, Graham B (2005) The Rhodiola Revolution: Transform Your Health With the Herbal Breakthrough of the 21st Century. New York, St Martins Press.
40. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260, 1814-1816.
41. Carelli RM (2004) Nucleus accumbens cell firing and rapid dopamine signaling during goal-directed behaviors in rats. Neuropharmacology 47(Suppl 1), 180-189.
42. Chen TJH, Blum K, Kaats G, Braverman ER, Eisenberg A, Sherman M, Davis K, Comings DE, Wood R, Pullin D, Arcuri V, Varshavski M, Mengucci JE, Blum SH, Downs BW, Meshkin B, Waite RL, Williams L, Schoolfield J, White L (2007) Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study. Gene Ther Mol Biol 11, 1-10.
43. Chen TJH, Blum, K, Payte JT, Schoolfield J, Hopper D, Stanford M, Braverman ER (2004) Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypoth 63, 538-548.
44. Cheng HY, Laviolette SR, van der Kooy D, Penninger JM (2004) DREAM ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine. Eur J Neurosci 19, 3033-3041.
45. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD (1995) Genetic variation in the β 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333, 352-354.
46. Colantuoni C, Rada P, McCarthy J, Patten C, Avena NM, Chadeayne A, Hoebel BG (2002) Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence. Obes Res 10, 478-488.
47. Cold JA (1996) NeuRecover-SA in the treatment of cocaine withdrawal and craving: a pilot study. Clin Drug Invest 12, 1-4.
48. Collaku A, Rankinen T, Rice T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C (2004) A genome-wide linkage scan for dietary energy and nutrient intakes: the health, risk factors, exercise training, and genetics (HERITAGE) family study. Am J Clin Nutr 79, 881-886.
49. Comings DE, Blum K (2000) Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 126, 325-41.
50. Comings DE, Flanagan SD, Dietz G, Muhleman D, Knell E, Gysin R (1993) The dopamine D2 receptor (DRD2) as a major gene in obesity and height. Biochem Med Metab Biol 50, 176-185.
51. Conti G, Blandini F, Tassorelli C, Giubilei F, Fornai F, Zocchi A, Orzi F (2001) Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia. Neurosci Let 309, 161-164.
52. Cooney CA, Dave AA, Wolff GL (2002) Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 132(supplement 8), S2393-S2400.
53. Cooper JR, Bloom FR, Roth RH (1966) The Biochemical Basis of Neuropharmacology. New York, Oxford University Press, pg 226.
54. Corthesy-Theulaz I, den Dunnen Jt, Fere P, Geurts JMW, Muller M, Belzen NV, van Ommen B (2005) Nutrigenomics: The impact of Biomics Technology on Nutrition Research. Ann Nutr Metab 49, 355-365.
55. Darwin F, Ed (1888) (Charles Darwin: Life and letters. London, Murray.).
56. Davies KM, Heaney RP, Recker RR, Lappe JM, Barger-Lux MJ, Rafferty K, Hinders S (2000) Calcium Intake and Body Weight. J Clin Endocrinol Metab 85, 4635-4638.
57. DeFrance JF, Hymel C, Trachtenberg MC, Ginsberg LD, Schweitzer FC, Estes S, Chen TJH, Braverman ER, Cull JG, Blum K (1997) Enhancement of attention processing by Kantrol in healthy humans: A pilot study. Clin Electroenceph 28, 68-75.
58. Deriaz O, Theriault G, Lavallee N, Fournier G, Nadeau A, Bouchard C ( 1991) Human resting energy expenditure in relation to dietary potassium. Am J Clin Nutr 54, 628-634.
59. Dhawan K, Dhawan S, Chhabra S (2003) Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a nonhabit forming anxiolytic. J Pharm Sci 6, 215-222.
60. Dhawan K, Dhawan S, Sharma A (2004) Passiflora: a review update. J Ethnopharmacol 94, 1-23.
61. Dhawan K, Kumar R, Kumar S, Sharma A (2001) Correct Identification of Passiflora incarnata Linn a Promising Herbal Anxiolytic and Sedative. J Med Food 4, 137-144.
62. Dhawan K, Kumar S, Sharma A (2002a) Beneficial effects of chrysin and benzoflavone on virility in 2-year-old male rats. J Med Food 5, 43-48.
63. Dhawan K, Kumar S, Sharma A (2002b) Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice. J Ethnopharmacol 81, 239-244.
64. Dhawan K, Kumar S, Sharma A (2002c) Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: a comment on medicinal plants' standardization. J Altern Complement Med 8, 283-291.
65. Dhawan K, Sharma A (2002) Prevention of chronic alcohol and nicotine-induced azospermia, sterility and decreased libido, by a novel tri-substituted benzoflavone moiety from Passiflora incamata Linneaus in healthy male rats. Life Sci 71, 3059-3069.
66. Dhawan K, Sharma A (2003) Restoration of chronic-Delta 9-THC-induced decline in sexuality in male rats by a novel benzoflavone moiety from Passiflora incarnata Linn. Br J Pharmacol 138, 117-120.
67. Di Chiara G, Acquas E, Tanda G, Cadoni C (1993) Drugs of abuse: biochemical surrogates of specific aspects of natural reward? Biochem Soc Symp 59, 65-81.
68. Downs BW, Bagchi M, Subbaraju GV, Shara MA, Preuss HG, Bagchi D (2005) Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid. Mutat Res 579, 149-162.
69. Dulloo AG, Jacquet J (1998) Adaptive reduction in basal metabolic rate in response to food deprivation in humans: a role for feedback signal from the fat stores. Am J Clin Nutr 68, 599-606.
70. Dulloo AG, Jacquet J (1999) The control of partitioning between protein and fat during human starvation: its internal determinants and biological significance. Brit J Nutr 82, 339-356.
71. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH (1996) Dopamine D4 receptor exon 111 polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12, 78-80.
72. Farooqi S, Rau H, Whitehead J, O'Rahilly S (2006) ob gene mutations and human obesity. Proc Nutr Soc 57, 471-475.
73. Filozof CM, Murua C, Sanchez MP, Brailovsky C, Perman M, Gonzalez CD, Ravussin E (2000) Low plasma leptin concentration and low rates of fat oxidation in weight-stable post-obese subjects. Obes Res 8, 205-210.
74. Gardner EL, Vorel SR (1998) Cannabinoid transmission and reward-related events. Neurobiol Dis 5, 502-533.
75. Gartside SE, Cowan PJ, Sharp T (1992) Effect of 5-hydroxy-1-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharm 31, 9-14.
76. Geller I, Blum K (1970) The effects of 5 HTP on para chlorphenylalanine (p CPA) attenuation of "conflict" behavior. Eur J Pharmacol 9, 319-324.
77. George SR, Cheng R, Nguyen T, Israel Y, O'Dowd BF (1993) Polymorphisms of the D4 dopamine receptor alleles in chronic alcoholism. Biochem Biophys Res Commun 196, 107-114.
78. Germano C, Ramazanov Z (1999) Artic Root (Rhodiola rosea). New York, Kensington Publishing Corp pg 45.
79. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22,1146-1154.
80. Gniuli D, Capristo E, Liverani E, Greco AV, Calvani M, Mingrone G ( 2005) Effects of binge eating behavior on fuel oxidation and body composition. J Am Coll Nutr 24, 244-249.
81. Goldman D, Urbanek M, Guenther D, Robin R, Long JC (1997) Linkage and association of a functional DRD2 variant (Ser311Cys) and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians. Am J Med Genet 74, 386-394.
82. Goldman D, Urbanek M, Guenther D, Robin R, Long JC (1998) A functionally deficient DRD2 variant (Ser311Cys) is not linked to alcoholism and substance abuse. Alcohol 16, 47-52.
83. Gray J, Yeo GS, Cox JJ, Morton J, Adlarn AL, Keogh JM, Yanovski JA, El Gharbawy A, Han JC, Tung YC, Hodges JR, Raymond FL, O'rahilly S, Farooqi IS (2006) Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 55, 3366-71.
84. Green AI, Zimmet SV, Strous RD, Schildkraut JJ (1999) Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 6, 287-96.
85. Greenwood MR, Cleary MP, Gruen R, Blase D, Stern JS, Triscari J, Sullivan AC (1981) Effect of (-)-hydroxycitrate on development of obesity in Zucker obese rat. Am J Physiol 240, E72-8.
86. Groop LC, Tuomi T (1997) Non-insulin-dependent diabetes mellitus--a collision between thrifty genes and an affluent society. Ann Med 29, 37-53.
87. Heaney RP (2003) Normalizing calcium intake: projected population effects for body weight. J Nutr 133, 268S-270S.
88. Heaney RP, Dowell MS, Bierman J, Hale CA, Bendich A (2001) Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 20, 239-246.
89. Hegele RA, Jugenberg M, Connelly PW, Jenkins DJA (1997) Evidence for gene -diet interaction in the response of blood pressure to dietary fiber. Nutr Res 17, 1229-1238.
90. Hill JO (2006) Understanding and Addressing the Epidemic of Obesity: An Energy Balance Perspective. Endocr Rev, in press).
91. Hu YJ, Diamond AM (2003) Role of glutathione peroxidase 1 in breast cancer: Loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63, 3347-3351.
92. Kaats GR, Blum K, Fisher JA, Adelman JA (1996) Effects of chromium picolinate supplementation of body composition: A randomized, double-masked, placebo-controlled study. Curr Ther Res 57, 747-756.
93. Kaats GR, Wise JA, Blum K, Morin RA, Adelman JD, Craig J, Croft HA ( 1992) The short term therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate caloric restriction. Curr Ther Res 51, 261-274.
94. Kasim S, Blake BL, Fan X, Chartoff E, Egami K, Breese GR, Hess EJ, Jinnah HA (2006) The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in rodents. Dev Neurosci 28, 505-517.
95. Kim KS, Lee KW, Lee KW, Im JY, Yoo JY, Kim SW, Lee JK, Nestler EJ, Han PL (2006) Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci 103, 3908-3913.
96. Kim KW, Kim HD, Jung JS, Woo RS, Kim HS, Suh HW, Kim YH, Song DK ( 2001) Characterization of antidepressant-like effects of p-synephrine stereoisomers. Naunyn Schmiedebergs Arch Pharmacol 364, 21-26.
97. Kogan HA, Marsden CA, Fone KC (2002) DR4004, a putative 5-HT (7) receptor antagonist, also has functional activity at the dopamine D2 receptor. Eur J Pharmacol 449, 105-111.
98. Koob GF, Bloom FE (1988) Cellular and molecular mechanism of drug dependence. Science 242, 715-723.
99. Koshimura K, Tanaka J, Murakami Y, Kato Y (2000) Effect of high concentration of glucose on dopamine release from Pheochromocytoma -12 cells. Metabolism 52, 922-926.
100. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Amer P (1997) Human β-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte β-2 adrenoceptor function. J Clin Invest 100, 3005-3013.
101. Levin BE (2001) Glucosensing neurons do more than just sense glucose. Int J Obes Relat Metab Disord Suppl 5, S68-72.
102. Levin BE (2000) Glucose-regulated dopamine release from substantia nigra neurons. Brain Res 874, 158-64.
103. Li T, Xu K, Deng H, Cai G, Liu J, Liu X, Wang R, Xiang X, Zhao J, Murray RM, Sham PC, Collier DA (1997) Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psych 2, 413-416.
104. Linazaroso G, van Blercom N, Lasa A (2004) Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa. Neurologia 19, 117-27.
105. Lochner C, Hemmings SM, Kinnear CJ, Niehaus DJ, Nel DG, Corfield VA, Moolman-Smook JC, Seedat S, Stein DJ (2005) Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry 46, 14-19.
106. Loe YC, Bergeron N, Rodriguez N, Schwarz JM (2001) Gas chromatography/mass spectrometry method to quantify blood hydroxycitrate concentration. Anal Biochem 292, 148-54.
107. Lowenstein JM (1971) Effect of (-)-Hydroxycitrate on Fatty Acid Synthesis by Rat Liver in Vivo. J Biol Chem 346620
108. Lowenstein JM, Brunengraber H, (1993) Effect of (-)-Hydroxycitrate On Ethanol Metabolism. FEBS Letters 36130.
109. Luan J, Brown PO, Harding Ah, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ (2001) Evidence for gene-nutrient interaction at the PPAR γ locus. Diabetes 50, 1625-1638.
110. Manzardo AM, Penick EC (2006) A theoretical argument for inherited thiamine insensitivity as one possible biological cause of familial alcoholism. Alcohol Clin Exp Res 30, 1545-50.
111. Milner JD, Irie K, Wurtman RJ (1986) Effect of phenylalanine on the release of endogenous dopamine from rat striatal slices. J Neurochem 47, 1444-1448.
112. Molla G, Sacchi S, Bernasconi M, Pilone MS, Fukui K, Polegioni L ( 2006) Characterization of human D-amino acid oxidase. FEBS Lett 580, 2358-64.
113. Mustafa AK, Kim PM, Snyder SH (2004) D-Serine as a putative glial neurotransmitter. Neuron Glia Biol 1, 275-281.
114. Nargund RP, Strack AM, Fong TM (2006) Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem 49, 4035-4043.
115. Nazar K, Kaciuba-Uscilko H, Szczepanik J, Zemba AW, Kruk B, Chwalbinska-Moneta J, Titow-Stupnicka E, Bicz B, Krotkiewski M (1996) Phosphate supplementation prevents a decrease of triiodothyronine and increases resting metabolic rate during low energy diet. J Physiol Pharmacol 47, 373-383.
116. Neel JV (1962) Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 14, 353-362.
117. Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, Fitch RJ, Ozkaragoz T, Sheridan PJ, Anglin MD, et al (1993 b) Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 33, 271-285.
118. Ottosson M, Lonnroth P, Bjorntorp P, Eden S (2000) Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinol Metab 85, 799-803.
119. Pan DA, Mater MK, Theen AP, Peters JM, Gonzalez FJ Jump DB (2000) Evidence against the peroxisome proloferator-activated receptor a (PPAR a) as the mediator fpr polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. J Lipid Res 41, 742-751.
120. Panossian A, Wagner H (2005) Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother Res 19, 819-38.
121. Perfumi M, Mattioli L (2007) Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytother Res 21, 37-43.
122. Ponce G, Jimenez-Arriero MA, Rubio G, Hoenicka J, Ampuero I, Ramos JA, Palomo T (2003) The A1 allele of the DRD2 gene (TaqI A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients. Eur Psychiatry 18, 356-360.
123. Poston WS 2nd, Ericsson M, Linder J, Haddock CK, Hanis CL, Nilsson T, Astrom M, Foreyt JP (1998) D4 dopamine receptor gene exon III polymorphism and obesity risk. Eat Weight Disord 3, 71-77.
124. Prentice AM, Rayoco-Solon P, Moore SE (2005) Insights from the developing world: thrifty genotypes and thrifty phenotypes. Proc Nutr Soc 64, 153-161.
125. Preuss HG, Bagchi D, Bagchi M, Rao CV, Dey DK, Satyanarayana S (2004) Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabet Obes Metab 6, 171-180.
126. Ramanazov Z, del Mar Bernard SM (1999) Effective natural stress and weight management using Rhodiola rosea and Rhododendron caucasicum. East Canaan, ATNS/Safe Goods Publishing.
127. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L, Bouchard C (2006) The human obesity gene map: the 2005 update. Obesity (Silver Spring) 14, 529-644.
128. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL (2001) Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 74, 694-700.
129. Rivier C, Rivier J, Vale W (1986) Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science 231, 607-609.
130. Ross J (2000) Amino-acid precursor and enkephalinase inhibition therapy: evidence for effectiveness in treatment of Reward Deficiency Syndrome (RDS), with particular emphasis on eating disorders. Mol Psych 6, S7.
131. Sakariah KK, Nageswara R (1988) Lipid-Lowering And Antiobesity Effect Of (-) Hydroxycitric Acid. Nutr Res 8, 209-212.
132. Sale C, Harris RC, Delves S, Corbett J (2006) Metabolic and physiological effects of ingesting extracts of bitter orange, green tea and guarana at rest and during treadmill walking in overweight males. Int J Obes (Lond) 30, 764-73.
133. Salmon AM, Evrard A, Damaj I, Changeux JP (2004) Reduction of withdrawal signs after chronic nicotine exposure of a-calcitonin gene-related peptide knock-out mice. Neurosci Lett 360, 73-76.
134. Shapses SA, Von Thun NL, Heymsfield SB, Ricci TA, Ospina M, Pierson RN Jr, Stahl T (2001) Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation. J Bone Miner Res 16, 1329-1336.
135. Shiroyama K, Moriwaki K, Yuge O (1998) The direct effect of dopamine on glucose release from primary cultured rat hepatocytes. In Vivo 12, 527-529.
136. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50, 488H and attenuates morphine withdrawal. EMBO J 17, 886-897.
137. Snyder SH, Kim PM (2000) D-amino acids as putative neurotransmitters: focus on D-sefine. Neurochem Res 25, 553-60.
138. Spanswick D, Smith MA, Mirshamsi S, Routh VH, Ashford ML (2000) Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 3, 757-758.
139. Spielbauer B, Stahl F (2005) Impact of microarray technology in nutrition and food research. Mol Nutr Food Res 49, 908-917.
140. Ssaratikov AS, Krasnov EA, Chnikina LA, Duvidson LM, Sotova MI, Marina TF, Nechoda MF, Axenova RA, Tscherdinzeff SG (1968) Rhodiolosid, a new glycoside from Rhodiola rosea and its pharmacological properties. Pharmazie 23, 392-5.
141. Stobbe M (2006) "Survey: Most obese claim to eat healthy." Associated Press. Accessed on October 1, 2006 on http://www.boston.com/yourlife/health/diseases/articles/2006/08/02/ survey_most_obese_claim_to_eat_healthy_1154518615/.
142. Sullivan AC, Hamilton JG, Miller ON, Wheatley VR (1972) Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. Arch Biochem Biophys 150, 183-90.
143. Teegarden D (2003) Calcium intake and reduction in weight or fat mass. J Nutr 133, 249S-251S.
144. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R (2001) Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem 78, 1094-1103.
145. Trijillo E, Davis C, Milner J (2006) Nutrigenetics, proteomics, metabolomics and the practice of dietetics. J Am Dietetic Association 106, 403-413.
146. Trugman JM, James CL (1993) D1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervation. Brain Res 607, 270-274.
147. Umhau JC, Petrulis SG, Diaz R, Rawlings R, George DT (2003) Blood glucose is correlated with cerebrospinal fluid neurotransmitter metabolites. Neuroendocrinology 78, 339-343.
148. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-97.
149. van Ommen B (2004) Nutrigenomics : exploiting systems biology in the nutrition and health arenas. Nutrition 20, 4-8.
150. Van Ommen B, Stierum R (2002) Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol 13, 517-521.
151. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14, 169-177.
152. Wald H, Garty H, Palmer LG, Popovtzer MM (1998) Differential regulation of ROMK expression in kidney cortex and medulla by aldosterone and potassium. Am J Physiol Renal Physiol 275, F239-F245.
153. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357, 354-357.
154. Ward SJ, Dykstra (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16, 381-388.
155. Wasada T (2002) Adenosine triphosphate-sensitive (K(ATP)) channel activity is coupled with insulin resistance in obesity and type 2 diabetes mellitus. Intern Med 41, 84-90.
156. Yeo, GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, O'Rahilly S, Farooqi IS (2004) A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7, 1187-1189.
157. Zemel MB (2003) Mechanisms of dairy modulation of adiposity. J Nutr 133, 252S-256S.
158. Zemel MB (2003) Role of dietary calcium and dairy products in modulating adiposity. Lipids 38, 139-146.